深化战略合作 国药控股与多家跨国药企开展深度业务交流

Core Viewpoint - China National Pharmaceutical Group (Sinopharm) is enhancing its strategic cooperation with leading global pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Eisai China, and Gilead Sciences through productive dialogues focused on current collaboration outcomes, future strategic alignment, and innovative business models [1] Group 1 - Sinopharm is engaging in effective discussions with multiple top-tier pharmaceutical firms [1] - The dialogues aim to inject new momentum into the ongoing strategic cooperation [1] - The focus includes exploring future strategic synergies and innovative business models [1]